Related Experiment Video
Updated: Dec 18, 2025
08:14
Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research
Published on: March 22, 2024
1.9K
Shock - Classification and Pathophysiological Principles of Therapeutics.
Olga N Kislitsina1,2, Jonathan D Rich2, Jane E Wilcox2
1Department of Cardiac Surgery Bluhm Cardiovascular Institute Feinberg School of Medicine Northwestern University Medical Center, Chicago, Illinois, IL, United States.
Current Cardiology Reviews
|December 14, 2018
Summary
Managing shock is complex due to diverse presentations and limited treatments. This review details current and novel vasopressor agents, including catecholamines and newer drugs, for effective shock management.
Area of Science:
- Cardiology
- Critical Care Medicine
- Pharmacology
Background:
- Shock management is challenging due to varied clinical presentations (cardiogenic, septic, hypovolemic) and therapeutic limitations.
- Current shock treatments rely on endogenous catecholamines (epinephrine, norepinephrine, dopamine) and established vasopressors like dobutamine and milrinone.
Purpose of the Study:
- To review the mechanism of action, dosage, efficacy, and safety of existing and novel agents for shock management.
- To elucidate key clinical trials underpinning contemporary shock therapy.
Main Methods:
- Comprehensive literature review of established and emerging pharmacologic agents for shock.
- Analysis of clinical trial data and mechanistic studies for vasopressors and inotropes.
Main Results:
- Established catecholamines and vasopressors remain mainstays in shock treatment.
- Newer agents (vasopressin, levosimendan, omecamtiv mecarbil, istaroxime, nesiritide) show promise but require further clinical outcome validation.
Conclusions:
- Understanding the nuances of different shock types and therapeutic options is crucial for optimal patient care.
- Further research is needed to confirm the clinical utility of novel agents in improving outcomes for complex shock cases.
Keywords:
Shockcardiogenic shockendogenous catecholaminesexogenous catecholaminesinotropesseptic shockshock therapyvasopressors.More Related Videos
Related Concept Videos
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
378
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
378
01:29Heart Failure II: Pathophysiology
573
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
573
01:24Blood Pressure Imbalances and Circulatory Shock
1.3K
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.3K
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
3.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.8K
01:17Pathophysiology of Heart Failure
2.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.5K
01:30Pulmonary Hypertension: Classification and Pathogenesis
479
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
479